 John Kinsella
Concepts (676)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nitric Oxide | 88 | 2023 | 914 | 7.570 |
Why?
| | Hernias, Diaphragmatic, Congenital | 26 | 2024 | 201 | 6.270 |
Why?
| | Persistent Fetal Circulation Syndrome | 37 | 2023 | 137 | 5.040 |
Why?
| | Respiratory Insufficiency | 29 | 2023 | 316 | 3.440 |
Why?
| | Hypertension, Pulmonary | 45 | 2023 | 1902 | 3.400 |
Why?
| | Extracorporeal Membrane Oxygenation | 30 | 2024 | 292 | 3.250 |
Why?
| | Bronchopulmonary Dysplasia | 18 | 2024 | 382 | 2.580 |
Why?
| | Administration, Inhalation | 70 | 2023 | 683 | 2.420 |
Why?
| | Infant, Newborn | 106 | 2024 | 6046 | 2.190 |
Why?
| | Infant, Premature | 31 | 2024 | 567 | 1.860 |
Why?
| | High-Frequency Ventilation | 20 | 2006 | 45 | 1.780 |
Why?
| | Hemodynamics | 40 | 2022 | 1110 | 1.770 |
Why?
| | Bronchodilator Agents | 12 | 2020 | 248 | 1.750 |
Why?
| | Respiratory Distress Syndrome, Newborn | 13 | 2011 | 106 | 1.650 |
Why?
| | Vasodilator Agents | 15 | 2022 | 331 | 1.640 |
Why?
| | Oxygen Inhalation Therapy | 10 | 2015 | 160 | 1.570 |
Why?
| | Pulmonary Circulation | 31 | 2006 | 430 | 1.400 |
Why?
| | Hernia, Diaphragmatic | 9 | 2021 | 65 | 1.380 |
Why?
| | Infant, Premature, Diseases | 6 | 2019 | 100 | 1.270 |
Why?
| | Ventricular Dysfunction, Left | 4 | 2022 | 389 | 1.220 |
Why?
| | Intensive Care Units | 7 | 2018 | 802 | 1.090 |
Why?
| | Respiration, Artificial | 25 | 2019 | 642 | 1.080 |
Why?
| | Hypoxia | 19 | 2021 | 1107 | 1.030 |
Why?
| | Oxygen | 21 | 2021 | 933 | 0.960 |
Why?
| | Vascular Resistance | 29 | 2021 | 372 | 0.930 |
Why?
| | Echocardiography | 13 | 2023 | 659 | 0.860 |
Why?
| | Humans | 170 | 2024 | 136783 | 0.840 |
Why?
| | Blood Gas Analysis | 7 | 2021 | 74 | 0.840 |
Why?
| | Gestational Age | 22 | 2024 | 902 | 0.820 |
Why?
| | Critical Care | 8 | 2017 | 583 | 0.810 |
Why?
| | Lung | 33 | 2023 | 4065 | 0.810 |
Why?
| | Transportation of Patients | 3 | 2020 | 54 | 0.790 |
Why?
| | Propofol | 5 | 2024 | 73 | 0.740 |
Why?
| | Bronchoconstriction | 1 | 2020 | 32 | 0.680 |
Why?
| | Ventricular Dysfunction | 1 | 2019 | 16 | 0.650 |
Why?
| | Sheep | 40 | 2007 | 855 | 0.650 |
Why?
| | Pulmonary Gas Exchange | 11 | 2009 | 121 | 0.640 |
Why?
| | Pre-Eclampsia | 2 | 2024 | 189 | 0.620 |
Why?
| | Heart Atria | 1 | 2020 | 136 | 0.610 |
Why?
| | Anaphylaxis | 1 | 2020 | 105 | 0.610 |
Why?
| | Fetus | 21 | 2018 | 806 | 0.610 |
Why?
| | Vasodilation | 20 | 2005 | 495 | 0.600 |
Why?
| | Cardiovascular System | 1 | 2020 | 139 | 0.600 |
Why?
| | Ductus Arteriosus, Patent | 4 | 2015 | 51 | 0.600 |
Why?
| | Infant | 35 | 2024 | 9442 | 0.590 |
Why?
| | Hospital Mortality | 6 | 2018 | 900 | 0.560 |
Why?
| | Severity of Illness Index | 14 | 2024 | 2831 | 0.550 |
Why?
| | Trachea | 2 | 2018 | 235 | 0.550 |
Why?
| | Critical Illness | 5 | 2017 | 807 | 0.550 |
Why?
| | Heart Ventricles | 3 | 2020 | 792 | 0.540 |
Why?
| | Early Medical Intervention | 2 | 2014 | 57 | 0.530 |
Why?
| | Anesthetics, Intravenous | 4 | 2024 | 47 | 0.530 |
Why?
| | Pain, Postoperative | 3 | 2024 | 267 | 0.520 |
Why?
| | Pulmonary Surfactants | 6 | 2021 | 106 | 0.520 |
Why?
| | Animals, Newborn | 18 | 2007 | 843 | 0.510 |
Why?
| | Monitoring, Physiologic | 3 | 2019 | 267 | 0.500 |
Why?
| | Endothelium-Dependent Relaxing Factors | 1 | 2015 | 16 | 0.500 |
Why?
| | Liver Cirrhosis | 2 | 2015 | 316 | 0.500 |
Why?
| | Prenatal Diagnosis | 1 | 2018 | 202 | 0.500 |
Why?
| | Hyaline Membrane Disease | 6 | 1998 | 20 | 0.490 |
Why?
| | Female | 81 | 2024 | 72840 | 0.490 |
Why?
| | Nerve Block | 1 | 2016 | 74 | 0.490 |
Why?
| | Blood Coagulation | 1 | 2017 | 253 | 0.490 |
Why?
| | Pulmonary Artery | 20 | 2021 | 1082 | 0.480 |
Why?
| | Ultrasonography, Interventional | 1 | 2016 | 142 | 0.480 |
Why?
| | Morphine | 1 | 2016 | 160 | 0.480 |
Why?
| | Radial Artery | 1 | 2015 | 68 | 0.470 |
Why?
| | Umbilical Arteries | 1 | 2015 | 54 | 0.470 |
Why?
| | Treatment Outcome | 26 | 2024 | 10764 | 0.460 |
Why?
| | Male | 64 | 2024 | 67361 | 0.440 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2016 | 147 | 0.440 |
Why?
| | Vitamin A | 1 | 2013 | 58 | 0.430 |
Why?
| | Practice Guidelines as Topic | 3 | 2020 | 1568 | 0.420 |
Why?
| | Superoxide Dismutase | 2 | 2006 | 346 | 0.420 |
Why?
| | Oxygen Consumption | 3 | 2015 | 696 | 0.410 |
Why?
| | Knowledge Bases | 1 | 2013 | 27 | 0.410 |
Why?
| | Vitamins | 1 | 2013 | 177 | 0.390 |
Why?
| | Conscious Sedation | 2 | 2010 | 91 | 0.390 |
Why?
| | Retrospective Studies | 27 | 2024 | 15564 | 0.370 |
Why?
| | Phosphodiesterase Inhibitors | 5 | 2013 | 89 | 0.370 |
Why?
| | Intestinal Obstruction | 1 | 2012 | 50 | 0.370 |
Why?
| | Alcohol-Related Disorders | 1 | 2013 | 124 | 0.360 |
Why?
| | Muscle, Smooth, Vascular | 8 | 2005 | 444 | 0.360 |
Why?
| | Anesthesia, General | 2 | 2005 | 73 | 0.350 |
Why?
| | Lung Diseases | 6 | 2010 | 768 | 0.340 |
Why?
| | Paresis | 1 | 2010 | 30 | 0.330 |
Why?
| | Emergency Medicine | 1 | 2013 | 224 | 0.330 |
Why?
| | Sulfones | 4 | 2013 | 110 | 0.320 |
Why?
| | Decision Support Systems, Clinical | 1 | 2013 | 218 | 0.320 |
Why?
| | Adrenal Insufficiency | 1 | 2010 | 31 | 0.320 |
Why?
| | Dietary Supplements | 1 | 2013 | 559 | 0.310 |
Why?
| | Nitric Oxide Synthase | 15 | 2005 | 240 | 0.310 |
Why?
| | Survival Rate | 14 | 2022 | 1969 | 0.310 |
Why?
| | Dipyridamole | 6 | 1998 | 28 | 0.300 |
Why?
| | Herniorrhaphy | 2 | 2020 | 60 | 0.300 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2010 | 216 | 0.290 |
Why?
| | Pacemaker, Artificial | 1 | 2009 | 119 | 0.290 |
Why?
| | Analgesics, Opioid | 1 | 2016 | 991 | 0.290 |
Why?
| | Nose | 2 | 2008 | 67 | 0.290 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2011 | 252 | 0.290 |
Why?
| | Meconium Aspiration Syndrome | 3 | 2003 | 11 | 0.280 |
Why?
| | Heart Defects, Congenital | 7 | 2022 | 831 | 0.280 |
Why?
| | Fluorocarbons | 2 | 1999 | 117 | 0.270 |
Why?
| | Cardiac Output | 8 | 2009 | 164 | 0.270 |
Why?
| | Foreign Bodies | 1 | 2008 | 104 | 0.260 |
Why?
| | Action Potentials | 1 | 2010 | 495 | 0.260 |
Why?
| | Anticoagulants | 2 | 2024 | 658 | 0.260 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2007 | 137 | 0.260 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3566 | 0.260 |
Why?
| | Pregnancy | 19 | 2024 | 6731 | 0.250 |
Why?
| | Animals | 60 | 2022 | 36768 | 0.250 |
Why?
| | Thyroidectomy | 2 | 2024 | 106 | 0.240 |
Why?
| | Child | 21 | 2022 | 21968 | 0.240 |
Why?
| | Piperazines | 3 | 2013 | 350 | 0.240 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2013 | 1042 | 0.230 |
Why?
| | Respiration Disorders | 1 | 2005 | 77 | 0.230 |
Why?
| | Neck Pain | 1 | 2024 | 26 | 0.220 |
Why?
| | Hirudins | 1 | 2024 | 53 | 0.220 |
Why?
| | Respiration | 3 | 2019 | 197 | 0.220 |
Why?
| | Muscle Stretching Exercises | 1 | 2024 | 19 | 0.220 |
Why?
| | Antithrombins | 1 | 2024 | 59 | 0.220 |
Why?
| | Tracheostomy | 2 | 2024 | 132 | 0.220 |
Why?
| | Preoperative Care | 3 | 2017 | 356 | 0.210 |
Why?
| | Postoperative Hemorrhage | 1 | 2024 | 87 | 0.210 |
Why?
| | Ventricular Function, Left | 6 | 2020 | 540 | 0.210 |
Why?
| | Heart | 3 | 2019 | 656 | 0.210 |
Why?
| | Ductus Arteriosus | 11 | 2005 | 73 | 0.210 |
Why?
| | Pulmonary Alveoli | 3 | 2021 | 405 | 0.210 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2020 | 2045 | 0.200 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2024 | 68 | 0.200 |
Why?
| | Heparin | 1 | 2024 | 258 | 0.200 |
Why?
| | Double-Blind Method | 4 | 2016 | 1981 | 0.200 |
Why?
| | Fatal Outcome | 4 | 2012 | 304 | 0.200 |
Why?
| | Nitrites | 1 | 2002 | 84 | 0.200 |
Why?
| | Prospective Studies | 11 | 2023 | 7583 | 0.200 |
Why?
| | Infant, Very Low Birth Weight | 2 | 2017 | 68 | 0.190 |
Why?
| | Antioxidants | 1 | 2006 | 578 | 0.190 |
Why?
| | Gastroesophageal Reflux | 2 | 2022 | 234 | 0.190 |
Why?
| | Respiratory Therapy | 3 | 2003 | 23 | 0.190 |
Why?
| | Risk Factors | 12 | 2024 | 10331 | 0.190 |
Why?
| | Incidence | 5 | 2015 | 2788 | 0.180 |
Why?
| | Prognosis | 7 | 2023 | 4018 | 0.180 |
Why?
| | Water-Electrolyte Imbalance | 1 | 2001 | 44 | 0.180 |
Why?
| | Precision Medicine | 2 | 2023 | 426 | 0.180 |
Why?
| | Vasoconstriction | 3 | 2005 | 202 | 0.170 |
Why?
| | Emergency Treatment | 1 | 2002 | 117 | 0.170 |
Why?
| | Neuromuscular Nondepolarizing Agents | 1 | 2020 | 17 | 0.170 |
Why?
| | Plethysmography | 1 | 2001 | 106 | 0.170 |
Why?
| | Peptide Fragments | 1 | 2024 | 707 | 0.170 |
Why?
| | Fundoplication | 1 | 2020 | 53 | 0.170 |
Why?
| | Respiratory Function Tests | 5 | 2019 | 596 | 0.170 |
Why?
| | Papio | 6 | 1995 | 93 | 0.170 |
Why?
| | Postoperative Complications | 6 | 2017 | 2624 | 0.160 |
Why?
| | Middle Aged | 19 | 2019 | 33200 | 0.160 |
Why?
| | Therapy, Computer-Assisted | 1 | 2020 | 62 | 0.160 |
Why?
| | Carbon Monoxide | 1 | 2000 | 80 | 0.160 |
Why?
| | Fluid Therapy | 2 | 2011 | 147 | 0.160 |
Why?
| | Time Factors | 12 | 2017 | 6792 | 0.160 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2019 | 1455 | 0.160 |
Why?
| | Blood Pressure | 13 | 2014 | 1772 | 0.160 |
Why?
| | Patient Care Team | 2 | 2016 | 627 | 0.160 |
Why?
| | Logistic Models | 6 | 2024 | 2060 | 0.160 |
Why?
| | Pulmonary Veins | 2 | 1999 | 99 | 0.160 |
Why?
| | Thrombelastography | 1 | 2020 | 153 | 0.160 |
Why?
| | Infusions, Intravenous | 4 | 2024 | 408 | 0.150 |
Why?
| | Aged | 15 | 2019 | 23729 | 0.150 |
Why?
| | Neoplasm Staging | 3 | 2018 | 1373 | 0.150 |
Why?
| | Predictive Value of Tests | 2 | 2017 | 2030 | 0.150 |
Why?
| | Combined Modality Therapy | 7 | 2017 | 1235 | 0.150 |
Why?
| | Blood Coagulation Disorders | 1 | 2020 | 173 | 0.150 |
Why?
| | United Kingdom | 3 | 2017 | 315 | 0.150 |
Why?
| | Treatment Failure | 5 | 2007 | 353 | 0.140 |
Why?
| | Risk | 3 | 2021 | 904 | 0.140 |
Why?
| | Return to Work | 1 | 2017 | 20 | 0.140 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2018 | 82 | 0.140 |
Why?
| | Single-Blind Method | 2 | 2013 | 286 | 0.140 |
Why?
| | Cerebral Hemorrhage | 2 | 2014 | 112 | 0.140 |
Why?
| | Heart Rate | 4 | 2009 | 823 | 0.140 |
Why?
| | Retinopathy of Prematurity | 1 | 2019 | 141 | 0.140 |
Why?
| | Abnormalities, Multiple | 1 | 2019 | 189 | 0.140 |
Why?
| | Intubation, Intratracheal | 2 | 2018 | 259 | 0.140 |
Why?
| | Pneumonectomy | 1 | 2019 | 154 | 0.140 |
Why?
| | Thiopental | 1 | 1997 | 4 | 0.140 |
Why?
| | Ondansetron | 1 | 1997 | 16 | 0.130 |
Why?
| | Biological Products | 1 | 2000 | 215 | 0.130 |
Why?
| | Adult | 18 | 2024 | 37616 | 0.130 |
Why?
| | Anesthesia, Spinal | 1 | 2016 | 7 | 0.130 |
Why?
| | Methemoglobin | 2 | 1993 | 21 | 0.130 |
Why?
| | Troponin I | 1 | 2017 | 84 | 0.130 |
Why?
| | Pulmonary Edema | 1 | 1997 | 106 | 0.130 |
Why?
| | Blood Circulation | 3 | 1998 | 41 | 0.130 |
Why?
| | Smoke Inhalation Injury | 3 | 1991 | 28 | 0.130 |
Why?
| | Follow-Up Studies | 10 | 2019 | 5115 | 0.130 |
Why?
| | Capillary Permeability | 1 | 1997 | 144 | 0.130 |
Why?
| | Dyspnea | 1 | 2018 | 251 | 0.130 |
Why?
| | Anesthesia, Local | 1 | 2016 | 18 | 0.130 |
Why?
| | Glycocalyx | 1 | 2016 | 28 | 0.130 |
Why?
| | Antiemetics | 1 | 1997 | 43 | 0.130 |
Why?
| | Injections, Spinal | 1 | 2016 | 106 | 0.130 |
Why?
| | Emergency Service, Hospital | 1 | 2008 | 2050 | 0.130 |
Why?
| | Cardiac Catheterization | 6 | 2022 | 527 | 0.130 |
Why?
| | Infant, Newborn, Diseases | 2 | 2014 | 113 | 0.130 |
Why?
| | Guidelines as Topic | 1 | 2018 | 276 | 0.130 |
Why?
| | Estradiol | 4 | 2001 | 518 | 0.130 |
Why?
| | Mentors | 1 | 2018 | 197 | 0.130 |
Why?
| | Echocardiography, Doppler | 2 | 2001 | 109 | 0.130 |
Why?
| | Colorectal Neoplasms | 2 | 2016 | 792 | 0.130 |
Why?
| | Multivariate Analysis | 3 | 2016 | 1513 | 0.130 |
Why?
| | Receptors, Platelet-Derived Growth Factor | 1 | 1996 | 15 | 0.130 |
Why?
| | Child, Preschool | 14 | 2017 | 11069 | 0.120 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2019 | 236 | 0.120 |
Why?
| | Survivors | 1 | 2019 | 487 | 0.120 |
Why?
| | Dimensional Measurement Accuracy | 1 | 2015 | 13 | 0.120 |
Why?
| | Disease Management | 2 | 2017 | 623 | 0.120 |
Why?
| | Employment | 1 | 2017 | 177 | 0.120 |
Why?
| | Down Syndrome | 1 | 2022 | 490 | 0.120 |
Why?
| | Thyroid Carcinoma, Anaplastic | 1 | 2016 | 34 | 0.120 |
Why?
| | Nitroarginine | 10 | 2005 | 56 | 0.120 |
Why?
| | Surgical Procedures, Operative | 1 | 2018 | 257 | 0.120 |
Why?
| | Length of Stay | 5 | 2017 | 1208 | 0.120 |
Why?
| | Chronic Disease | 8 | 2013 | 1784 | 0.120 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 738 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2018 | 497 | 0.120 |
Why?
| | Neutrophils | 3 | 1999 | 1234 | 0.120 |
Why?
| | Hypnotics and Sedatives | 2 | 2024 | 199 | 0.120 |
Why?
| | Radiography | 2 | 2008 | 829 | 0.120 |
Why?
| | Faculty, Medical | 1 | 2018 | 282 | 0.120 |
Why?
| | Cerebrovascular Circulation | 3 | 1995 | 240 | 0.120 |
Why?
| | Risk Assessment | 4 | 2017 | 3429 | 0.110 |
Why?
| | Postoperative Care | 1 | 2016 | 257 | 0.110 |
Why?
| | Sildenafil Citrate | 4 | 2021 | 58 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 318 | 0.110 |
Why?
| | Statistics as Topic | 1 | 2015 | 311 | 0.110 |
Why?
| | Ventilator Weaning | 2 | 2005 | 36 | 0.110 |
Why?
| | Mothers | 1 | 2020 | 752 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2011 | 544 | 0.110 |
Why?
| | Ammonia | 2 | 1992 | 62 | 0.110 |
Why?
| | Vasopressins | 1 | 2014 | 64 | 0.110 |
Why?
| | Continuity of Patient Care | 1 | 2016 | 278 | 0.110 |
Why?
| | Registries | 5 | 2022 | 2015 | 0.110 |
Why?
| | Thrombosis | 1 | 2017 | 367 | 0.110 |
Why?
| | Biomarkers | 4 | 2016 | 4158 | 0.110 |
Why?
| | Pediatrics | 2 | 2019 | 1112 | 0.100 |
Why?
| | Vasoconstrictor Agents | 1 | 2014 | 138 | 0.100 |
Why?
| | Alcohol Withdrawal Delirium | 1 | 2013 | 8 | 0.100 |
Why?
| | Elective Surgical Procedures | 2 | 2011 | 180 | 0.100 |
Why?
| | Survival Analysis | 3 | 2009 | 1319 | 0.100 |
Why?
| | Clinical Trials as Topic | 3 | 2008 | 1043 | 0.100 |
Why?
| | Hypotension | 1 | 2014 | 122 | 0.100 |
Why?
| | Epoprostenol | 3 | 2021 | 136 | 0.100 |
Why?
| | Pilot Projects | 5 | 2024 | 1697 | 0.100 |
Why?
| | Hemorrhage | 1 | 2017 | 723 | 0.100 |
Why?
| | Cell Nucleus | 1 | 1996 | 614 | 0.100 |
Why?
| | Cyclic GMP | 4 | 2001 | 93 | 0.100 |
Why?
| | Coronary Circulation | 2 | 1995 | 141 | 0.100 |
Why?
| | Critical Care Nursing | 1 | 2013 | 36 | 0.100 |
Why?
| | Diaphragm | 2 | 2023 | 42 | 0.100 |
Why?
| | Renal Dialysis | 1 | 2016 | 434 | 0.100 |
Why?
| | Vascular Diseases | 1 | 2015 | 244 | 0.090 |
Why?
| | Aged, 80 and over | 4 | 2017 | 7569 | 0.090 |
Why?
| | Early Diagnosis | 1 | 2013 | 243 | 0.090 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2011 | 9 | 0.090 |
Why?
| | Delivery Rooms | 1 | 2011 | 7 | 0.090 |
Why?
| | Recombinant Proteins | 2 | 2024 | 1354 | 0.090 |
Why?
| | Cohort Studies | 5 | 2024 | 5718 | 0.090 |
Why?
| | Troponin | 1 | 2011 | 51 | 0.090 |
Why?
| | Ventilators, Mechanical | 2 | 2016 | 58 | 0.090 |
Why?
| | Kidney Tubules | 1 | 1992 | 117 | 0.090 |
Why?
| | Acetylcholine | 5 | 2001 | 186 | 0.090 |
Why?
| | Algorithms | 3 | 2013 | 1686 | 0.090 |
Why?
| | Patient Admission | 1 | 2013 | 191 | 0.090 |
Why?
| | Case-Control Studies | 2 | 2018 | 3537 | 0.090 |
Why?
| | Respiratory Mechanics | 3 | 1999 | 67 | 0.090 |
Why?
| | Diseases in Twins | 1 | 2012 | 175 | 0.090 |
Why?
| | Cardiac Output, Low | 1 | 1991 | 66 | 0.090 |
Why?
| | Death, Sudden, Cardiac | 1 | 2012 | 184 | 0.090 |
Why?
| | Alfentanil | 1 | 2010 | 3 | 0.090 |
Why?
| | Monitoring, Intraoperative | 2 | 2008 | 56 | 0.080 |
Why?
| | Oocyte Retrieval | 1 | 2010 | 12 | 0.080 |
Why?
| | Delivery, Obstetric | 1 | 1991 | 145 | 0.080 |
Why?
| | Nitric Oxide Synthase Type III | 7 | 2007 | 204 | 0.080 |
Why?
| | Vitamin D Deficiency | 1 | 2012 | 184 | 0.080 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2011 | 165 | 0.080 |
Why?
| | Communication | 1 | 2016 | 869 | 0.080 |
Why?
| | Thermodilution | 2 | 2005 | 13 | 0.080 |
Why?
| | DNA-Binding Proteins | 2 | 2007 | 1500 | 0.080 |
Why?
| | Disease Models, Animal | 7 | 2007 | 4279 | 0.080 |
Why?
| | Endothelium, Vascular | 5 | 2016 | 925 | 0.080 |
Why?
| | Platelet-Derived Growth Factor | 2 | 2003 | 91 | 0.080 |
Why?
| | APACHE | 2 | 2017 | 69 | 0.080 |
Why?
| | Physicians | 1 | 2018 | 897 | 0.080 |
Why?
| | Abdomen | 1 | 2010 | 125 | 0.080 |
Why?
| | Positive-Pressure Respiration | 2 | 2000 | 80 | 0.080 |
Why?
| | Thoracic Surgical Procedures | 1 | 2010 | 73 | 0.080 |
Why?
| | Airway Obstruction | 1 | 1991 | 162 | 0.080 |
Why?
| | Endothelin Receptor Antagonists | 3 | 1998 | 62 | 0.080 |
Why?
| | Analysis of Variance | 6 | 2014 | 1318 | 0.080 |
Why?
| | Endothelins | 3 | 2000 | 64 | 0.080 |
Why?
| | Vitamin D | 1 | 2012 | 395 | 0.080 |
Why?
| | Prostaglandins | 2 | 2001 | 97 | 0.070 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2011 | 250 | 0.070 |
Why?
| | Hospitalization | 1 | 2018 | 2195 | 0.070 |
Why?
| | Anesthetics, Combined | 1 | 2008 | 9 | 0.070 |
Why?
| | Regional Blood Flow | 4 | 1998 | 474 | 0.070 |
Why?
| | Patient Readmission | 1 | 2013 | 695 | 0.070 |
Why?
| | Point-of-Care Systems | 1 | 2010 | 163 | 0.070 |
Why?
| | Scotland | 2 | 2018 | 18 | 0.070 |
Why?
| | Chest Wall Oscillation | 1 | 2007 | 4 | 0.070 |
Why?
| | Transcription Factors | 1 | 1996 | 1714 | 0.070 |
Why?
| | Hydrocortisone | 1 | 2010 | 317 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 551 | 0.070 |
Why?
| | Receptors, Endothelin | 3 | 2000 | 51 | 0.070 |
Why?
| | Postoperative Period | 3 | 2016 | 343 | 0.070 |
Why?
| | Acute Disease | 2 | 2005 | 1006 | 0.070 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 2 | 1998 | 17 | 0.070 |
Why?
| | Sex Distribution | 1 | 2008 | 376 | 0.070 |
Why?
| | Lung Neoplasms | 2 | 2019 | 2491 | 0.070 |
Why?
| | Neoplasms | 2 | 2019 | 2644 | 0.070 |
Why?
| | Microspheres | 3 | 1991 | 137 | 0.070 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2004 | 108 | 0.070 |
Why?
| | Leukomalacia, Periventricular | 1 | 2006 | 8 | 0.070 |
Why?
| | Purines | 3 | 2013 | 176 | 0.060 |
Why?
| | Piperidines | 1 | 2008 | 205 | 0.060 |
Why?
| | Swine | 2 | 2003 | 773 | 0.060 |
Why?
| | Endothelin-1 | 5 | 2000 | 181 | 0.060 |
Why?
| | Intracranial Hemorrhages | 1 | 2006 | 84 | 0.060 |
Why?
| | Methyl Ethers | 1 | 2005 | 13 | 0.060 |
Why?
| | Atrial Natriuretic Factor | 2 | 1996 | 56 | 0.060 |
Why?
| | Enzyme Inhibitors | 7 | 2005 | 838 | 0.060 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2010 | 1055 | 0.060 |
Why?
| | Lung Compliance | 1 | 2005 | 49 | 0.060 |
Why?
| | Cross-Over Studies | 2 | 1998 | 560 | 0.060 |
Why?
| | Airway Resistance | 1 | 2005 | 36 | 0.060 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2005 | 43 | 0.060 |
Why?
| | Signal Transduction | 3 | 2005 | 5065 | 0.060 |
Why?
| | Anesthetics, Inhalation | 1 | 2005 | 35 | 0.060 |
Why?
| | Electroencephalography | 1 | 2008 | 433 | 0.060 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 277 | 0.060 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2007 | 241 | 0.060 |
Why?
| | Prenatal Care | 1 | 2007 | 287 | 0.060 |
Why?
| | Electric Impedance | 1 | 2005 | 107 | 0.060 |
Why?
| | Longitudinal Studies | 2 | 2006 | 2847 | 0.060 |
Why?
| | Aging | 2 | 1992 | 1861 | 0.060 |
Why?
| | Amides | 1 | 2005 | 93 | 0.060 |
Why?
| | Pulmonary Wedge Pressure | 2 | 2022 | 69 | 0.060 |
Why?
| | Drug Administration Schedule | 4 | 2011 | 783 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1294 | 0.050 |
Why?
| | Rats | 7 | 2005 | 5628 | 0.050 |
Why?
| | Carbon Dioxide | 4 | 1999 | 267 | 0.050 |
Why?
| | Carcinoma | 2 | 2016 | 236 | 0.050 |
Why?
| | Home Nursing | 1 | 2003 | 25 | 0.050 |
Why?
| | Cost-Benefit Analysis | 3 | 2011 | 584 | 0.050 |
Why?
| | Bronchoalveolar Lavage | 1 | 2003 | 93 | 0.050 |
Why?
| | Coronary Artery Bypass | 1 | 2005 | 238 | 0.050 |
Why?
| | Birth Weight | 1 | 2006 | 514 | 0.050 |
Why?
| | Esophagus | 1 | 2005 | 255 | 0.050 |
Why?
| | Endothelial Growth Factors | 1 | 2002 | 64 | 0.050 |
Why?
| | Disability Evaluation | 1 | 2024 | 289 | 0.050 |
Why?
| | Lymphokines | 1 | 2002 | 131 | 0.050 |
Why?
| | Embryonic and Fetal Development | 3 | 2000 | 96 | 0.050 |
Why?
| | Intermittent Positive-Pressure Ventilation | 2 | 1993 | 11 | 0.050 |
Why?
| | Surgical Flaps | 1 | 2023 | 130 | 0.050 |
Why?
| | Forced Expiratory Volume | 2 | 2016 | 532 | 0.050 |
Why?
| | Age Factors | 3 | 2016 | 3290 | 0.050 |
Why?
| | Stomach | 1 | 2002 | 110 | 0.050 |
Why?
| | Mouth Mucosa | 1 | 2022 | 92 | 0.050 |
Why?
| | Analgesics | 1 | 2024 | 205 | 0.050 |
Why?
| | Sequence Deletion | 1 | 2022 | 183 | 0.050 |
Why?
| | Mosaicism | 1 | 2022 | 73 | 0.050 |
Why?
| | Evaluation Studies as Topic | 2 | 1992 | 177 | 0.050 |
Why?
| | Forkhead Transcription Factors | 1 | 2022 | 190 | 0.050 |
Why?
| | Thyroid Neoplasms | 2 | 2016 | 337 | 0.050 |
Why?
| | Cross-Sectional Studies | 1 | 2013 | 5417 | 0.050 |
Why?
| | Estrogen Antagonists | 1 | 2001 | 45 | 0.050 |
Why?
| | Phenotype | 2 | 2023 | 3199 | 0.050 |
Why?
| | Uterus | 1 | 2002 | 215 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2002 | 379 | 0.040 |
Why?
| | Milrinone | 1 | 2021 | 29 | 0.040 |
Why?
| | Muscle, Smooth | 2 | 2000 | 155 | 0.040 |
Why?
| | Ligation | 5 | 2002 | 87 | 0.040 |
Why?
| | Labor, Obstetric | 1 | 2001 | 61 | 0.040 |
Why?
| | Calibration | 1 | 2001 | 145 | 0.040 |
Why?
| | Protoporphyrins | 1 | 2000 | 16 | 0.040 |
Why?
| | Injections, Intra-Arterial | 1 | 2000 | 27 | 0.040 |
Why?
| | Surveys and Questionnaires | 1 | 2013 | 5749 | 0.040 |
Why?
| | Self Report | 1 | 2024 | 825 | 0.040 |
Why?
| | Patient Transfer | 1 | 2002 | 165 | 0.040 |
Why?
| | Hydrocarbons, Brominated | 1 | 1999 | 4 | 0.040 |
Why?
| | Inflammation | 1 | 2010 | 2834 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2019 | 116 | 0.040 |
Why?
| | Potassium Channel Blockers | 1 | 1999 | 37 | 0.040 |
Why?
| | Blotting, Northern | 4 | 2000 | 199 | 0.040 |
Why?
| | Adolescent | 8 | 2005 | 21463 | 0.040 |
Why?
| | Angiography | 1 | 1999 | 207 | 0.040 |
Why?
| | Constriction, Pathologic | 1 | 1999 | 241 | 0.040 |
Why?
| | Esophageal Neoplasms | 1 | 2002 | 324 | 0.040 |
Why?
| | Receptors, Estrogen | 1 | 2001 | 436 | 0.040 |
Why?
| | Digestive System Physiological Phenomena | 1 | 1998 | 4 | 0.040 |
Why?
| | Drug Synergism | 2 | 1998 | 378 | 0.040 |
Why?
| | Leukocyte Count | 2 | 1997 | 330 | 0.040 |
Why?
| | Asphyxia Neonatorum | 1 | 1998 | 18 | 0.040 |
Why?
| | Acidosis | 2 | 1992 | 101 | 0.040 |
Why?
| | Blood Vessels | 1 | 2000 | 187 | 0.040 |
Why?
| | Body Weight | 2 | 2005 | 981 | 0.040 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 1998 | 50 | 0.040 |
Why?
| | Immunohistochemistry | 4 | 2005 | 1731 | 0.030 |
Why?
| | Occipital Bone | 1 | 1997 | 18 | 0.030 |
Why?
| | Receptor, Endothelin A | 4 | 2000 | 64 | 0.030 |
Why?
| | Cephalometry | 1 | 1997 | 33 | 0.030 |
Why?
| | Frontal Bone | 1 | 1997 | 21 | 0.030 |
Why?
| | Disease Progression | 2 | 2017 | 2750 | 0.030 |
Why?
| | Potassium Channels | 1 | 1998 | 150 | 0.030 |
Why?
| | Growth | 1 | 1997 | 60 | 0.030 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2002 | 682 | 0.030 |
Why?
| | Arterial Pressure | 1 | 2017 | 125 | 0.030 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2016 | 26 | 0.030 |
Why?
| | Syndecan-1 | 1 | 2016 | 38 | 0.030 |
Why?
| | Blood Pressure Determination | 1 | 2017 | 156 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 1998 | 2903 | 0.030 |
Why?
| | Ventricular Function, Right | 1 | 2019 | 283 | 0.030 |
Why?
| | Expectorants | 1 | 2016 | 24 | 0.030 |
Why?
| | Arteriovenous Shunt, Surgical | 1 | 2016 | 18 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1997 | 182 | 0.030 |
Why?
| | Nausea | 1 | 1997 | 111 | 0.030 |
Why?
| | Endothelin-3 | 1 | 1996 | 3 | 0.030 |
Why?
| | Body Height | 1 | 1997 | 199 | 0.030 |
Why?
| | Vascular Patency | 1 | 2016 | 105 | 0.030 |
Why?
| | Interferon-Stimulated Gene Factor 3 | 1 | 1996 | 1 | 0.030 |
Why?
| | Ireland | 1 | 2016 | 30 | 0.030 |
Why?
| | Patient Selection | 1 | 2000 | 689 | 0.030 |
Why?
| | Rats, Inbred Strains | 3 | 1992 | 361 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2017 | 268 | 0.030 |
Why?
| | Interrupted Time Series Analysis | 1 | 2016 | 66 | 0.030 |
Why?
| | Arginine | 2 | 1994 | 271 | 0.030 |
Why?
| | Arteriovenous Fistula | 1 | 2016 | 36 | 0.030 |
Why?
| | Vomiting | 1 | 1997 | 129 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 1996 | 37 | 0.030 |
Why?
| | Gastrostomy | 1 | 1997 | 112 | 0.030 |
Why?
| | Kidney | 3 | 1991 | 1463 | 0.030 |
Why?
| | Lung Injury | 2 | 2011 | 218 | 0.030 |
Why?
| | Substance Withdrawal Syndrome | 1 | 1998 | 179 | 0.030 |
Why?
| | Luciferases | 1 | 1996 | 150 | 0.030 |
Why?
| | Stroke Volume | 1 | 2019 | 619 | 0.030 |
Why?
| | Blotting, Western | 3 | 2005 | 1225 | 0.030 |
Why?
| | Steroids | 1 | 2016 | 167 | 0.030 |
Why?
| | Enteral Nutrition | 1 | 1997 | 200 | 0.030 |
Why?
| | Genetic Counseling | 1 | 2015 | 76 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 1999 | 1483 | 0.030 |
Why?
| | Genes, Reporter | 1 | 1996 | 268 | 0.030 |
Why?
| | Tyrosine | 1 | 1996 | 222 | 0.030 |
Why?
| | Indiana | 1 | 2015 | 33 | 0.030 |
Why?
| | Ventilator-Induced Lung Injury | 1 | 2015 | 59 | 0.030 |
Why?
| | Nitric Oxide Synthase Type II | 3 | 2001 | 173 | 0.030 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2001 | 607 | 0.030 |
Why?
| | Peptides, Cyclic | 4 | 1998 | 259 | 0.030 |
Why?
| | Biological Transport | 3 | 1991 | 411 | 0.030 |
Why?
| | Aorta | 4 | 1998 | 417 | 0.030 |
Why?
| | Primary Prevention | 1 | 2016 | 196 | 0.030 |
Why?
| | Psychomotor Performance | 1 | 1997 | 312 | 0.030 |
Why?
| | Endothelium | 1 | 1995 | 122 | 0.030 |
Why?
| | Base Sequence | 2 | 1996 | 2180 | 0.030 |
Why?
| | Organ Dysfunction Scores | 1 | 2014 | 47 | 0.030 |
Why?
| | Self Efficacy | 1 | 2017 | 394 | 0.030 |
Why?
| | Costs and Cost Analysis | 2 | 2009 | 205 | 0.030 |
Why?
| | Infant, Low Birth Weight | 1 | 2015 | 141 | 0.030 |
Why?
| | Cardiovascular Agents | 1 | 2015 | 160 | 0.030 |
Why?
| | Vasomotor System | 3 | 2002 | 47 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2016 | 654 | 0.030 |
Why?
| | Life Support Care | 1 | 2014 | 32 | 0.030 |
Why?
| | Blood Flow Velocity | 2 | 1992 | 412 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 1996 | 378 | 0.030 |
Why?
| | Stress, Mechanical | 3 | 2001 | 480 | 0.030 |
Why?
| | Schools, Medical | 1 | 2015 | 146 | 0.030 |
Why?
| | Area Under Curve | 1 | 2014 | 313 | 0.030 |
Why?
| | Drug Evaluation | 1 | 1993 | 84 | 0.030 |
Why?
| | Acute Lung Injury | 1 | 2016 | 288 | 0.030 |
Why?
| | In Vitro Techniques | 2 | 1992 | 1089 | 0.030 |
Why?
| | Reference Values | 3 | 2002 | 817 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 1996 | 663 | 0.030 |
Why?
| | Young Adult | 1 | 2009 | 13126 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 1997 | 488 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 2015 | 331 | 0.020 |
Why?
| | Prevalence | 1 | 2019 | 2712 | 0.020 |
Why?
| | United States | 3 | 2012 | 14660 | 0.020 |
Why?
| | Lactic Acid | 1 | 2014 | 306 | 0.020 |
Why?
| | DNA | 2 | 1998 | 1458 | 0.020 |
Why?
| | Hypertension | 1 | 2002 | 1284 | 0.020 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2012 | 63 | 0.020 |
Why?
| | ROC Curve | 1 | 2014 | 545 | 0.020 |
Why?
| | Lung Transplantation | 1 | 2015 | 308 | 0.020 |
Why?
| | Child Development | 1 | 1997 | 471 | 0.020 |
Why?
| | Ammonium Chloride | 1 | 1992 | 5 | 0.020 |
Why?
| | Brain Chemistry | 1 | 1992 | 118 | 0.020 |
Why?
| | Decision Making | 1 | 2019 | 896 | 0.020 |
Why?
| | Streptococcus agalactiae | 1 | 1993 | 93 | 0.020 |
Why?
| | Brain | 2 | 1997 | 2669 | 0.020 |
Why?
| | Nephrons | 1 | 1992 | 18 | 0.020 |
Why?
| | Quality of Life | 2 | 2017 | 2868 | 0.020 |
Why?
| | Liver | 1 | 2020 | 1938 | 0.020 |
Why?
| | Isotonic Solutions | 1 | 2011 | 38 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 1995 | 362 | 0.020 |
Why?
| | United States Food and Drug Administration | 1 | 2012 | 207 | 0.020 |
Why?
| | Asthma | 1 | 2005 | 2290 | 0.020 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 2 | 2001 | 77 | 0.020 |
Why?
| | Odds Ratio | 1 | 2014 | 1063 | 0.020 |
Why?
| | Streptococcal Infections | 1 | 1993 | 151 | 0.020 |
Why?
| | Carboxyhemoglobin | 1 | 1991 | 7 | 0.020 |
Why?
| | Radioisotopes | 1 | 1991 | 31 | 0.020 |
Why?
| | Phosphorylation | 1 | 1996 | 1756 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2012 | 219 | 0.020 |
Why?
| | Patient Discharge | 1 | 2017 | 896 | 0.020 |
Why?
| | Fetal Diseases | 2 | 2003 | 173 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 1996 | 1250 | 0.020 |
Why?
| | Body Constitution | 1 | 1991 | 55 | 0.020 |
Why?
| | Hypertrophy, Right Ventricular | 2 | 2003 | 145 | 0.020 |
Why?
| | Ultrasonography | 1 | 2015 | 751 | 0.020 |
Why?
| | Intensive Care Units, Pediatric | 1 | 1993 | 233 | 0.020 |
Why?
| | Models, Cardiovascular | 1 | 1992 | 195 | 0.020 |
Why?
| | Echovirus Infections | 1 | 1990 | 1 | 0.020 |
Why?
| | Sex Factors | 1 | 2016 | 2068 | 0.020 |
Why?
| | RNA, Messenger | 3 | 2007 | 2831 | 0.020 |
Why?
| | Enterovirus B, Human | 1 | 1990 | 26 | 0.020 |
Why?
| | Preoperative Period | 1 | 2010 | 130 | 0.020 |
Why?
| | Meningoencephalitis | 1 | 1990 | 25 | 0.020 |
Why?
| | Medical Audit | 1 | 2010 | 76 | 0.020 |
Why?
| | Burns | 2 | 1991 | 323 | 0.020 |
Why?
| | Guanidines | 2 | 2001 | 40 | 0.020 |
Why?
| | Isoenzymes | 2 | 2001 | 304 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2009 | 113 | 0.020 |
Why?
| | Cyclooxygenase Inhibitors | 2 | 2001 | 79 | 0.020 |
Why?
| | Hospital Costs | 1 | 2010 | 119 | 0.020 |
Why?
| | Tetraethylammonium | 2 | 1999 | 16 | 0.020 |
Why?
| | 4-Aminopyridine | 2 | 1999 | 24 | 0.020 |
Why?
| | Pressure | 2 | 2002 | 222 | 0.020 |
Why?
| | Macrophages, Alveolar | 1 | 1991 | 392 | 0.020 |
Why?
| | Constriction | 2 | 1999 | 48 | 0.020 |
Why?
| | Heart Diseases | 1 | 1992 | 359 | 0.020 |
Why?
| | Immunologic Techniques | 2 | 1999 | 40 | 0.020 |
Why?
| | Cells, Cultured | 1 | 1996 | 4194 | 0.020 |
Why?
| | Cardiography, Impedance | 1 | 2007 | 8 | 0.020 |
Why?
| | Organ Size | 2 | 2005 | 477 | 0.020 |
Why?
| | Receptor, Endothelin B | 2 | 2000 | 50 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 1024 | 0.020 |
Why?
| | Heart Rate, Fetal | 2 | 1999 | 21 | 0.020 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2007 | 22 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 1990 | 654 | 0.020 |
Why?
| | Immediate-Early Proteins | 1 | 2007 | 49 | 0.020 |
Why?
| | Protein Precursors | 2 | 2000 | 132 | 0.020 |
Why?
| | Developmental Disabilities | 1 | 2009 | 264 | 0.020 |
Why?
| | Acute Kidney Injury | 1 | 2014 | 811 | 0.020 |
Why?
| | RNA, Viral | 1 | 1990 | 651 | 0.020 |
Why?
| | Proteins | 1 | 1992 | 1009 | 0.020 |
Why?
| | Comorbidity | 1 | 2010 | 1611 | 0.020 |
Why?
| | Thoracic Diseases | 1 | 2005 | 14 | 0.010 |
Why?
| | Respiratory Muscles | 1 | 2005 | 33 | 0.010 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 1987 | 193 | 0.010 |
Why?
| | Oscillometry | 1 | 2005 | 37 | 0.010 |
Why?
| | Phosphates | 1 | 1986 | 183 | 0.010 |
Why?
| | Manometry | 1 | 2005 | 95 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2005 | 86 | 0.010 |
Why?
| | Hypertrophy | 1 | 2005 | 132 | 0.010 |
Why?
| | Colorado | 1 | 2015 | 4491 | 0.010 |
Why?
| | Muscular Diseases | 1 | 2005 | 114 | 0.010 |
Why?
| | Drug Combinations | 1 | 2005 | 344 | 0.010 |
Why?
| | Pulse Therapy, Drug | 1 | 2003 | 7 | 0.010 |
Why?
| | Research Design | 1 | 2010 | 1107 | 0.010 |
Why?
| | Administration, Intranasal | 1 | 2003 | 90 | 0.010 |
Why?
| | Time | 1 | 2003 | 82 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 2007 | 504 | 0.010 |
Why?
| | Pharyngectomy | 1 | 2002 | 3 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 973 | 0.010 |
Why?
| | Hypopharyngeal Neoplasms | 1 | 2002 | 4 | 0.010 |
Why?
| | Speech, Alaryngeal | 1 | 2002 | 3 | 0.010 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 29 | 0.010 |
Why?
| | Pyrroles | 1 | 2004 | 211 | 0.010 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2002 | 79 | 0.010 |
Why?
| | Laryngectomy | 1 | 2002 | 19 | 0.010 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2003 | 44 | 0.010 |
Why?
| | Clinical Competence | 1 | 2010 | 1093 | 0.010 |
Why?
| | Carrier Proteins | 1 | 1987 | 768 | 0.010 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2002 | 77 | 0.010 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2002 | 57 | 0.010 |
Why?
| | Nifedipine | 1 | 2002 | 29 | 0.010 |
Why?
| | Meclofenamic Acid | 1 | 2001 | 10 | 0.010 |
Why?
| | 8-Bromo Cyclic Adenosine Monophosphate | 1 | 2001 | 21 | 0.010 |
Why?
| | Cyclooxygenase 1 | 1 | 2001 | 27 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2002 | 148 | 0.010 |
Why?
| | Electrocardiography | 1 | 2005 | 628 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2002 | 430 | 0.010 |
Why?
| | Infusions, Intra-Arterial | 1 | 2001 | 59 | 0.010 |
Why?
| | Glucocorticoids | 1 | 1986 | 596 | 0.010 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2001 | 68 | 0.010 |
Why?
| | Lymph Node Excision | 1 | 2002 | 170 | 0.010 |
Why?
| | Amidines | 1 | 2001 | 14 | 0.010 |
Why?
| | Benzylamines | 1 | 2001 | 41 | 0.010 |
Why?
| | Esophagectomy | 1 | 2002 | 131 | 0.010 |
Why?
| | Pulmonary Ventilation | 1 | 2001 | 79 | 0.010 |
Why?
| | Calcium Channels | 1 | 2002 | 159 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2002 | 167 | 0.010 |
Why?
| | Organ Specificity | 1 | 2001 | 304 | 0.010 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2001 | 158 | 0.010 |
Why?
| | Indoles | 1 | 2004 | 410 | 0.010 |
Why?
| | Cyclooxygenase 2 | 1 | 2001 | 178 | 0.010 |
Why?
| | Ligands | 1 | 2003 | 664 | 0.010 |
Why?
| | Drug Interactions | 1 | 2001 | 405 | 0.010 |
Why?
| | Calcium | 1 | 1986 | 1197 | 0.010 |
Why?
| | Physical Stimulation | 1 | 2000 | 65 | 0.010 |
Why?
| | Lung Volume Measurements | 1 | 1999 | 46 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2005 | 2481 | 0.010 |
Why?
| | Charybdotoxin | 1 | 1999 | 4 | 0.010 |
Why?
| | Atrial Function, Right | 1 | 1998 | 12 | 0.010 |
Why?
| | Lung Diseases, Interstitial | 1 | 2005 | 634 | 0.010 |
Why?
| | Delayed Rectifier Potassium Channels | 1 | 1998 | 9 | 0.010 |
Why?
| | Shab Potassium Channels | 1 | 1998 | 18 | 0.010 |
Why?
| | Digestive System | 1 | 1998 | 28 | 0.010 |
Why?
| | Electric Conductivity | 1 | 1998 | 88 | 0.010 |
Why?
| | Xenopus | 1 | 1998 | 86 | 0.010 |
Why?
| | Isothiuronium | 1 | 1998 | 3 | 0.010 |
Why?
| | Thiazines | 1 | 1998 | 10 | 0.010 |
Why?
| | Masks | 1 | 1998 | 62 | 0.010 |
Why?
| | Long-Term Care | 1 | 1998 | 100 | 0.010 |
Why?
| | DNA, Complementary | 1 | 1998 | 269 | 0.010 |
Why?
| | Catheterization | 1 | 1998 | 179 | 0.010 |
Why?
| | Gene Expression | 1 | 2003 | 1499 | 0.010 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2002 | 856 | 0.010 |
Why?
| | Medical Records | 1 | 1998 | 172 | 0.010 |
Why?
| | Oocytes | 1 | 1998 | 175 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1998 | 534 | 0.010 |
Why?
| | Methylene Blue | 1 | 1996 | 23 | 0.010 |
Why?
| | Dogs | 1 | 1998 | 409 | 0.010 |
Why?
| | Indomethacin | 1 | 1996 | 81 | 0.010 |
Why?
| | Microvilli | 2 | 1987 | 78 | 0.010 |
Why?
| | Adenosine | 1 | 1998 | 226 | 0.010 |
Why?
| | Staining and Labeling | 1 | 1996 | 146 | 0.010 |
Why?
| | Carcinoma, Papillary, Follicular | 1 | 1995 | 8 | 0.010 |
Why?
| | Purinones | 1 | 1995 | 4 | 0.010 |
Why?
| | Purinergic P1 Receptor Antagonists | 1 | 1995 | 8 | 0.010 |
Why?
| | Cardiomegaly | 1 | 1997 | 175 | 0.010 |
Why?
| | Receptors, Purinergic P1 | 1 | 1995 | 26 | 0.010 |
Why?
| | Adenocarcinoma, Follicular | 1 | 1995 | 36 | 0.010 |
Why?
| | Sodium | 2 | 1987 | 214 | 0.010 |
Why?
| | Theophylline | 1 | 1995 | 67 | 0.010 |
Why?
| | Arterioles | 1 | 1995 | 52 | 0.010 |
Why?
| | Carcinoma, Papillary | 1 | 1995 | 81 | 0.010 |
Why?
| | Home Care Services | 1 | 1998 | 255 | 0.010 |
Why?
| | Neurotransmitter Agents | 1 | 1995 | 82 | 0.010 |
Why?
| | Renal Circulation | 1 | 1995 | 58 | 0.010 |
Why?
| | Phenylephrine | 1 | 1995 | 75 | 0.010 |
Why?
| | Adrenal Glands | 1 | 1995 | 77 | 0.010 |
Why?
| | Viper Venoms | 1 | 1994 | 9 | 0.010 |
Why?
| | Muscle Tonus | 1 | 1994 | 21 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1998 | 2145 | 0.010 |
Why?
| | Neoplasm Invasiveness | 1 | 1995 | 507 | 0.010 |
Why?
| | Forecasting | 1 | 1995 | 384 | 0.010 |
Why?
| | Cause of Death | 1 | 1995 | 429 | 0.010 |
Why?
| | Perfusion | 1 | 1994 | 211 | 0.010 |
Why?
| | Intestines | 1 | 1995 | 359 | 0.010 |
Why?
| | Chemotaxis | 1 | 1991 | 130 | 0.010 |
Why?
| | Extracellular Matrix | 1 | 1995 | 527 | 0.010 |
Why?
| | Electrophoresis, Agar Gel | 1 | 1990 | 26 | 0.010 |
Why?
| | Macrophage Activation | 1 | 1991 | 201 | 0.010 |
Why?
| | Agammaglobulinemia | 1 | 1990 | 34 | 0.010 |
Why?
| | Nucleic Acid Hybridization | 1 | 1990 | 190 | 0.010 |
Why?
| | Gene Amplification | 1 | 1990 | 105 | 0.010 |
Why?
| | Cell Count | 1 | 1990 | 321 | 0.000 |
Why?
| | Myocardial Contraction | 1 | 1990 | 340 | 0.000 |
Why?
| | Adenocarcinoma | 1 | 1995 | 936 | 0.000 |
Why?
| | Eosinophils | 1 | 1990 | 331 | 0.000 |
Why?
| | Kidney Cortex | 1 | 1987 | 26 | 0.000 |
Why?
| | Sodium-Hydrogen Exchangers | 1 | 1987 | 24 | 0.000 |
Why?
| | Polymerase Chain Reaction | 1 | 1990 | 1059 | 0.000 |
Why?
| | Monocytes | 1 | 1990 | 561 | 0.000 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1987 | 564 | 0.000 |
Why?
| | Skin | 1 | 1990 | 745 | 0.000 |
Why?
| | Glomerular Filtration Rate | 1 | 1987 | 744 | 0.000 |
Why?
| | Macrophages | 1 | 1990 | 1541 | 0.000 |
Why?
|
|
Kinsella's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|